Retour

Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease

Health Health

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD). Topline efficacy data is expected in June.

GlobeNewswire Inc. • 09/05/2024 à 13:30:00
Annovis Bio, Inc.
Address: 101 LINDENWOOD DRIVE, SUITE 225
Postal Code: 19355
City: MALVERN
State: PA
Phone Number: 484-875-3192
Website: https://www.annovisbio.com
Status: Active
Company Info

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

List Date2020-01-29
MarketStocks
LocalUS
Primary ExchangeXNYS
TypeCS
Currency NameUSD
CIK0001477845
Composite figiBBG00PN9XD40
Share Class figiBBG00PN9XDJ4
Market Cap92,834,999 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees6
Share Class Shares Outstanding11170000
Weighted Shares Outstanding11171480
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
8.29
8.154
8.8
8.52
6.86
Variance
1.66%
-7.45%
5.26%
24.2%
13.78%
Open
8.155
8.81
8.36
6.86
6.029
Highest
8.45
9.053
10.085
8.545
7.242
Lowest
8.45
9.035
9.829
8.545
7.214
History
PeriodVarhighestlowest
1 week
37.5%
7.242
7.214
1 month
-17.18%
11.63
5.243
3 month
-34.09%
23.619
5.243
6 month
39.09%
6.48
5.243
1 year
-39.18%
14.7
5.243
3 year
-70.9%
28.86
5.243
5 year
25.04%
10.61
2.418
10 year
25.04%
10.61
2.418
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-14 2023-11-08 UNPUB
Assets 25,547,363 22,816,484 10,223,106 UNPUB
Current Assets 25,547,363 22,816,484 10,223,106 UNPUB
Current Liabilities 5,411,290 2,073,849 3,564,896 UNPUB
Equity 20,136,073 20,742,635 6,658,210 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 20,136,073 20,742,635 6,658,210 UNPUB
Liabilities 5,411,290 2,073,849 3,564,896 UNPUB
Liabilities And Equity 25,547,363 22,816,484 10,223,106 UNPUB
Noncurrent Assets 0 0 0 UNPUB
Noncurrent Liabilities 0 0 0 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-14 2023-11-08 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 UNPUB
Net Cash Flow, Continuing 0 0 0 UNPUB
Net Cash Flow From Financing Activities 7,386 8,572,191 0 UNPUB
Net Cash Flow From Financing Activities, Continuing 7,386 8,572,191 0 UNPUB
Net Cash Flow From Investing Activities 11,618,927 1,034,137 9,369,687 UNPUB
Net Cash Flow From Investing Activities, Continuing 11,618,927 1,034,137 9,369,687 UNPUB
Net Cash Flow From Operating Activities -11,626,313 -9,606,328 -9,369,687 UNPUB
Net Cash Flow From Operating Activities, Continuing -11,626,313 -9,606,328 -9,369,687 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-14 2023-11-08 UNPUB
Comprehensive Income/Loss -9,737,181 -9,537,122 -14,716,616 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -9,737,181 -9,537,122 -14,716,616 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-14 2023-11-08 UNPUB
Basic Earnings Per Share -1 -1 -2 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -2 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -9,737,181 -9,537,122 -14,716,616 UNPUB
Income/Loss From Continuing Operations Before Tax -9,737,181 -9,537,122 -14,716,616 UNPUB
Income Tax Expense/Benefit 0 0 0 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -9,737,181 -9,537,122 -14,716,616 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -9,737,181 -9,537,122 -14,716,616 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -9,737,181 -9,537,122 -14,716,616 UNPUB
Operating Expenses 9,969,716 9,759,700 14,863,271 UNPUB
Operating Income/Loss -9,969,716 -9,759,700 -14,863,271 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-08 2023-03-31
Assets 44,097,580 39,967,218 37,118,428 36,022,069
Current Assets 44,097,580 39,967,218 37,118,428 36,022,069
Current Liabilities 1,397,122 1,299,385 2,526,535 7,698,539
Equity 42,700,458 38,667,833 34,591,893 28,323,530
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 42,700,458 38,667,833 34,591,893 28,323,530
Liabilities 1,397,122 1,299,385 2,526,535 7,698,539
Liabilities And Equity 44,097,580 39,967,218 37,118,428 36,022,069
Noncurrent Assets 0 0 0 0
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-08 2023-03-31
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities 4,613 0 0 4,613
Net Cash Flow From Financing Activities, Continuing 4,613 0 0 4,613
Net Cash Flow From Investing Activities 3,017,176 6,694,587 3,987,160 17,308,321
Net Cash Flow From Investing Activities, Continuing 3,017,176 6,694,587 3,987,160 17,308,321
Net Cash Flow From Operating Activities -3,021,789 -6,694,587 -3,987,160 -17,312,934
Net Cash Flow From Operating Activities, Continuing -3,021,789 -6,694,587 -3,987,160 -17,312,934
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-08 2023-03-31
Comprehensive Income/Loss -5,234,063 -5,936,386 -6,431,951 -25,328,567
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -5,234,063 -5,936,386 -6,431,951 -25,328,567
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-08 2023-03-31
Basic Earnings Per Share -1 -1 -1 -3
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -1 -3
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -5,234,063 -5,936,386 -6,431,951 -25,328,567
Income/Loss From Continuing Operations Before Tax -5,234,063 -5,936,386 -6,431,951 -25,328,567
Income Tax Expense/Benefit 0 0 0 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -5,234,063 -5,936,386 -6,431,951 -25,328,567
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -5,234,063 -5,936,386 -6,431,951 -25,328,567
Net Income/Loss Available To Common Stockholders, Basic -5,234,063 -5,936,386 -6,431,951 -25,328,567
Operating Expenses 5,253,712 5,972,410 6,484,837 25,511,279
Operating Income/Loss -5,253,712 -5,972,410 -6,484,837 -25,511,279
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-28 2021-11-03 2022-03-02
Assets 5,964,956 49,496,238 47,650,490 46,001,478
Current Assets 5,964,956 49,496,238 47,650,490 46,001,478
Current Liabilities 1,596,681 884,075 1,120,601 1,506,514
Equity 4,368,275 48,612,163 46,529,889 44,494,964
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 4,368,275 48,612,163 46,529,889 44,494,964
Liabilities 1,596,681 884,075 1,120,601 1,506,514
Liabilities And Equity 5,964,956 49,496,238 47,650,490 46,001,478
Noncurrent Assets 0 0 0 0
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-28 2021-11-03 2022-03-02
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities 3,017 46,765,954 -25,456 46,743,515
Net Cash Flow From Financing Activities, Continuing 3,017 46,765,954 -25,456 46,743,515
Net Cash Flow From Investing Activities 2,471,851 -43,621,391 1,768,864 -37,611,356
Net Cash Flow From Investing Activities, Continuing 2,471,851 -43,621,391 1,768,864 -37,611,356
Net Cash Flow From Operating Activities -2,474,868 -3,144,563 -1,743,408 -9,132,159
Net Cash Flow From Operating Activities, Continuing -2,474,868 -3,144,563 -1,743,408 -9,132,159
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-28 2021-11-03 2022-03-02
Comprehensive Income/Loss -3,199,673 -2,524,602 -2,848,216 -14,487,132
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -3,199,673 -2,524,602 -2,848,216 -14,487,132
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-28 2021-11-03 2022-03-02
Basic Earnings Per Share UNPUB UNPUB 0 -2
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB 0 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -3,199,673 -2,524,602 -2,848,216 -14,487,132
Income/Loss From Continuing Operations Before Tax -3,199,673 -2,524,602 -2,848,216 -14,487,132
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -3,199,673 -2,524,602 -2,848,216 -14,487,132
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -3,199,673 -2,524,602 -2,848,216 -14,487,132
Net Income/Loss Available To Common Stockholders, Basic -3,199,673 -2,524,602 -2,848,216 -14,487,132
Operating Expenses 3,229,210 2,534,150 2,853,770 14,537,221
Operating Income/Loss -3,229,210 -2,534,150 -2,853,770 -14,537,221
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-07-29 2020-11-04 2021-03-03
Assets 11,441,186 10,201,216 9,402,001 8,119,334
Current Assets 11,441,186 10,201,216 9,402,001 8,119,334
Current Liabilities 749,299 702,936 281,058 578,380
Equity 10,691,887 9,498,280 9,120,943 7,540,954
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 10,691,887 9,498,280 9,120,943 7,540,954
Liabilities 749,299 702,936 281,058 578,380
Liabilities And Equity 11,441,186 10,201,216 9,402,001 8,119,334
Noncurrent Assets 0 0 0 0
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-07-29 2020-11-04 2021-03-03
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities 12,089,012 -45,389 0 12,043,623
Net Cash Flow From Financing Activities, Continuing 12,089,012 -45,389 0 12,043,623
Net Cash Flow From Investing Activities -11,118,607 1,357,195 922,663 -8,072,800
Net Cash Flow From Investing Activities, Continuing -11,118,607 1,357,195 922,663 -8,072,800
Net Cash Flow From Operating Activities -970,405 -1,311,806 -922,663 -3,970,823
Net Cash Flow From Operating Activities, Continuing -970,405 -1,311,806 -922,663 -3,970,823
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-07-29 2020-11-04 2021-03-03
Comprehensive Income/Loss -441,590 -2,309,490 -1,006,354 -5,462,047
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -441,590 -2,309,490 -1,006,354 -5,462,047
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-07-29 2020-11-04 2021-03-03
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -441,590 -2,309,490 -1,006,354 -5,462,047
Income/Loss From Continuing Operations Before Tax -441,590 -2,309,490 -1,006,354 -5,462,047
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -441,590 -2,309,490 -1,006,354 -5,462,047
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -441,590 -2,309,490 -1,006,354 -5,462,047
Net Income/Loss Available To Common Stockholders, Basic -441,590 -2,309,490 -1,006,354 -5,462,047
Operating Expenses 583,162 2,543,629 1,603,757 6,640,221
Operating Income/Loss -583,162 -2,543,629 -1,603,757 -6,640,221
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
★
15:30
United States
200.000
-31400.000
★
15:30
United States
61800.000
62600.000
★
15:30
United States
1300.000
1300.000
★
15:30
United States
-25300.000
-9700.000
★
15:30
United States
204500.000
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:ANVS240517P00022500 OPASPS Put American 100 22.5 BATO 2024-05-17
O:ANVS240517P00020000 OPASPS Put American 100 20 BATO 2024-05-17
O:ANVS240517P00017500 OPASPS Put American 100 17.5 BATO 2024-05-17
O:ANVS240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:ANVS240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:ANVS240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:ANVS240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:ANVS240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:ANVS240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:ANVS240517C00022500 OCASPS Call American 100 22.5 BATO 2024-05-17
O:ANVS240517C00020000 OCASPS Call American 100 20 BATO 2024-05-17
O:ANVS240517C00017500 OCASPS Call American 100 17.5 BATO 2024-05-17
O:ANVS240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:ANVS240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:ANVS240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:ANVS240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:ANVS240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:ANVS240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:ANVS240517P00035000 OPASPS Put American 100 35 BATO 2024-05-17
O:ANVS240517P00030000 OPASPS Put American 100 30 BATO 2024-05-17
O:ANVS240517P00025000 OPASPS Put American 100 25 BATO 2024-05-17
O:ANVS240517C00035000 OCASPS Call American 100 35 BATO 2024-05-17
O:ANVS240517C00030000 OCASPS Call American 100 30 BATO 2024-05-17
O:ANVS240517C00025000 OCASPS Call American 100 25 BATO 2024-05-17
O:ANVS240419P00040000 OPASPS Put American 100 40 BATO 2024-04-19
O:ANVS240419P00037500 OPASPS Put American 100 37.5 BATO 2024-04-19
O:ANVS240419P00035000 OPASPS Put American 100 35 BATO 2024-04-19
O:ANVS240419P00032500 OPASPS Put American 100 32.5 BATO 2024-04-19
O:ANVS240419P00030000 OPASPS Put American 100 30 BATO 2024-04-19
O:ANVS240419P00027500 OPASPS Put American 100 27.5 BATO 2024-04-19
O:ANVS240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:ANVS240419P00022500 OPASPS Put American 100 22.5 BATO 2024-04-19
O:ANVS240419P00020000 OPASPS Put American 100 20 BATO 2024-04-19
O:ANVS240419P00017500 OPASPS Put American 100 17.5 BATO 2024-04-19
O:ANVS240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:ANVS240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:ANVS240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:ANVS240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:ANVS240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:ANVS240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:ANVS240419C00040000 OCASPS Call American 100 40 BATO 2024-04-19
O:ANVS240419C00037500 OCASPS Call American 100 37.5 BATO 2024-04-19
O:ANVS240419C00035000 OCASPS Call American 100 35 BATO 2024-04-19
O:ANVS240419C00032500 OCASPS Call American 100 32.5 BATO 2024-04-19
O:ANVS240419C00030000 OCASPS Call American 100 30 BATO 2024-04-19
O:ANVS240419C00027500 OCASPS Call American 100 27.5 BATO 2024-04-19
O:ANVS240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:ANVS240419C00022500 OCASPS Call American 100 22.5 BATO 2024-04-19
O:ANVS240419C00020000 OCASPS Call American 100 20 BATO 2024-04-19
O:ANVS240419C00017500 OCASPS Call American 100 17.5 BATO 2024-04-19
O:ANVS240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:ANVS240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:ANVS240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:ANVS240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:ANVS240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:ANVS240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:ANVS240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:ANVS240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:ANVS240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:ANVS240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:ANVS240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:ANVS240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:ANVS240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:ANVS240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:ANVS240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:ANVS240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:ANVS240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:ANVS240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:ANVS240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:ANVS240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:ANVS240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:ANVS240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:ANVS240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:ANVS240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:ANVS240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:ANVS240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:ANVS240216P00017500 OPASPS Put American 100 17.5 BATO 2024-02-16
O:ANVS240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:ANVS240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:ANVS240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:ANVS240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:ANVS240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:ANVS240216C00017500 OCASPS Call American 100 17.5 BATO 2024-02-16
O:ANVS240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:ANVS240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:ANVS240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:ANVS240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:ANVS240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:ANVS240216P00040000 OPASPS Put American 100 40 BATO 2024-02-16
O:ANVS240216P00037500 OPASPS Put American 100 37.5 BATO 2024-02-16
O:ANVS240216P00035000 OPASPS Put American 100 35 BATO 2024-02-16
O:ANVS240216P00032500 OPASPS Put American 100 32.5 BATO 2024-02-16
O:ANVS240216P00030000 OPASPS Put American 100 30 BATO 2024-02-16
O:ANVS240216P00027500 OPASPS Put American 100 27.5 BATO 2024-02-16
O:ANVS240216P00025000 OPASPS Put American 100 25 BATO 2024-02-16
O:ANVS240216P00022500 OPASPS Put American 100 22.5 BATO 2024-02-16
O:ANVS240216P00020000 OPASPS Put American 100 20 BATO 2024-02-16
O:ANVS240216C00040000 OCASPS Call American 100 40 BATO 2024-02-16
O:ANVS240216C00037500 OCASPS Call American 100 37.5 BATO 2024-02-16
O:ANVS240216C00035000 OCASPS Call American 100 35 BATO 2024-02-16
O:ANVS240216C00032500 OCASPS Call American 100 32.5 BATO 2024-02-16
O:ANVS240216C00030000 OCASPS Call American 100 30 BATO 2024-02-16
O:ANVS240216C00027500 OCASPS Call American 100 27.5 BATO 2024-02-16
O:ANVS240216C00025000 OCASPS Call American 100 25 BATO 2024-02-16
O:ANVS240216C00022500 OCASPS Call American 100 22.5 BATO 2024-02-16
O:ANVS240216C00020000 OCASPS Call American 100 20 BATO 2024-02-16
O:ANVS240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:ANVS240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:ANVS240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:ANVS240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:ANVS240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:ANVS240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:ANVS240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:ANVS240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:ANVS240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:ANVS240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:ANVS240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:ANVS240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:ANVS240119P00040000 OPASPS Put American 100 40 BATO 2024-01-19
O:ANVS240119P00037500 OPASPS Put American 100 37.5 BATO 2024-01-19
O:ANVS240119P00035000 OPASPS Put American 100 35 BATO 2024-01-19
O:ANVS240119P00032500 OPASPS Put American 100 32.5 BATO 2024-01-19
O:ANVS240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:ANVS240119P00027500 OPASPS Put American 100 27.5 BATO 2024-01-19
O:ANVS240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:ANVS240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:ANVS240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:ANVS240119C00040000 OCASPS Call American 100 40 BATO 2024-01-19
O:ANVS240119C00037500 OCASPS Call American 100 37.5 BATO 2024-01-19
O:ANVS240119C00035000 OCASPS Call American 100 35 BATO 2024-01-19
O:ANVS240119C00032500 OCASPS Call American 100 32.5 BATO 2024-01-19
O:ANVS240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:ANVS240119C00027500 OCASPS Call American 100 27.5 BATO 2024-01-19
O:ANVS240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:ANVS240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:ANVS240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:ANVS240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:ANVS240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:ANVS240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:ANVS240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
News Stream
Stocks Earnings Releases and Operating Results
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results.
GlobeNewswire Inc. • 6d ago
Health Health
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD). Topline efficacy data is expected in June.
GlobeNewswire Inc. • 1w ago
Stocks Major shareholder announcements
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps.
GlobeNewswire Inc. • 1w ago
News Clinical Study
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer’s (AD) and Parkinson’s disease (PD), today announced the data from its Phase II/III Alzheimer study of buntanetap in mild to moderate AD patients. Based on these data, the Company plans to conduct a pivotal Phase III trial in biomarker-positive early AD patients.
GlobeNewswire Inc. • 2w ago
News News
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • 1mo ago
Stocks Earnings Releases and Operating Results
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
GlobeNewswire Inc. • 1mo ago
News News
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 211.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • 1mo ago
News Clinical Study
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April.
GlobeNewswire Inc. • 2mo ago
News News
Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?
Investors need to pay close attention to Annovis Bio (ANVS) stock based on the movements in the options market lately.
Zacks Investment Research • 2mo ago
News Clinical Study
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD).
GlobeNewswire Inc. • 3mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT